1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On March 30, 2026, Crown Reserve Acquisition Corp. I (CRAC) signed a Business Combination Agreement with Carvix, Inc., a Delaware corporation, under which Carvix would merge into a subsidiary of the SPAC and survive as a wholly owned subsidiary. Carvix stockholders would receive 50,000,001 SPAC common shares at closing, plus up to 50,000,100 earnout shares over four years, which would dilute existing SPAC shareholders.
Agreement signed March 30, 2026, with Carvix, Inc.; the SPAC would first domesticate to Delaware.
Carvix stockholders to receive 50,000,001 shares at the Effective Time, plus up to 50,000,100 earnout shares.
Earnout split equally between EBITDA targets (first year $10.38 million) and revenue targets (first year $276.8 million), with payment years starting January 1, 2027.
Either party may terminate if closing has not occurred by September 30, 2026, the Outside Date.
AbbVie said its first-quarter 2026 results will include $744 million in pre-tax acquired IPR&D and milestones expense, reducing both GAAP and adjusted diluted EPS by $0.41. Full-year 2026 adjusted EPS guidance falls to $13.96-$14.16 from the $14.37-$14.57 range given on February 4, 2026, and AbbVie says its guidance excludes any such expense incurred after the first quarter. Shareholders face a lower earnings outlook, and the quarter's results have not been finalized.
Q1 2026 acquired IPR&D and milestones expense of $744 million pre-tax, an unfavorable $0.41 impact on GAAP and adjusted diluted EPS
Full-year 2026 adjusted diluted EPS guidance now $13.96-$14.16, versus $14.37-$14.57 previously
Q1 2026 adjusted diluted EPS guidance now $2.56-$2.60, versus $2.97-$3.01 before the charge
Quarter ended March 31, 2026 results not finalized and may differ from these preliminary estimates
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.